These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 11814765

  • 1. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000.
    Koeth LM, Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Appelbaum PC.
    Int J Antimicrob Agents; 2002 Jan; 19(1):33-7. PubMed ID: 11814765
    [Abstract] [Full Text] [Related]

  • 2. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.
    Blondeau JM, Vaughan D, Laskowski R, Borsos S, Canadian Antimicrobial Study Group.
    Int J Antimicrob Agents; 2001 Jun; 17(6):457-64. PubMed ID: 11397615
    [Abstract] [Full Text] [Related]

  • 3. Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project.
    Marchese A, Debbia EA, Schito GC.
    J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():11-5. PubMed ID: 10997594
    [Abstract] [Full Text] [Related]

  • 4. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens.
    Rittenhouse S, McCloskey L, Broskey J, Niconovich N, Jakielaszek C, Poupard J, Coleman K.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():23-7. PubMed ID: 10824028
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
    Morrissey I, Robbins M, Viljoen L, Brown DF.
    J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
    [Abstract] [Full Text] [Related]

  • 6. Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.
    García-Garrote F, Cercenado E, Martín-Pedroviejo J, Cuevas O, Bouza E.
    J Antimicrob Chemother; 2001 May; 47(5):681-4. PubMed ID: 11328784
    [Abstract] [Full Text] [Related]

  • 7. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA, Ehrhardt AF, Jones RN.
    Am J Med; 2001 Dec 17; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [Abstract] [Full Text] [Related]

  • 8. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
    Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN, Alexander Project Group.
    J Antimicrob Chemother; 2003 Aug 17; 52(2):229-46. PubMed ID: 12865398
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q, Xu Y, Chen M, Wang H, Sun H, Hu Y, Zhang R, Duan Q, Zhuo C, Cao B, Liu Y, Yu Y, Sun Z, Chu Y.
    Diagn Microbiol Infect Dis; 2012 Jun 17; 73(2):187-91. PubMed ID: 22521692
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).
    Deshpande LM, Jones RN.
    Diagn Microbiol Infect Dis; 2000 Jun 17; 37(2):139-42. PubMed ID: 10863108
    [Abstract] [Full Text] [Related]

  • 11. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).
    Jones RN, Biedenbach DJ.
    Diagn Microbiol Infect Dis; 2003 Apr 17; 45(4):273-8. PubMed ID: 12729999
    [Abstract] [Full Text] [Related]

  • 12. [Resistance study of community respiratory pathogens isolated in China from 2005 to 2007].
    Sun HL, Yang QW, Xu YC, Wang H, Xie XL, Chen MJ, Zhang XZ, Liu Y, Ye HF, Sun ZY, Duan Q, Ni YX, Yu YS, Zhao WS, He L, Wang J, Ji P, Liu PP, Zhang LX.
    Zhonghua Yi Xue Za Zhi; 2009 Nov 17; 89(42):2983-7. PubMed ID: 20137709
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
    Küçükbasmaci O, Gönüllü N, Aktaş Z, Gürol D, Berkiten R.
    Int J Antimicrob Agents; 2003 Nov 17; 22(5):497-501. PubMed ID: 14602368
    [Abstract] [Full Text] [Related]

  • 14. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
    Lopez H, Vilches V, Scarano S, Stepanik D, Smayevsky J, Lemme L, Cardeñosa O, Ambler J, Sucari A.
    Int J Antimicrob Agents; 2001 Oct 17; 18(4):379-82. PubMed ID: 11691572
    [Abstract] [Full Text] [Related]

  • 15. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
    Wise R, Andrews JM.
    J Chemother; 1998 Aug 17; 10(4):276-9. PubMed ID: 9720464
    [Abstract] [Full Text] [Related]

  • 16. Activity of gatifloxacin compared to those of seven agents against bacteria recovered from outpatients with respiratory tract infection.
    Smayevsky J, Lopez H, Di Chiara M, Scarano S, Lanza A, Vilches V, Stepanik D, Bantar C, Sucari A.
    Diagn Microbiol Infect Dis; 2000 Aug 17; 37(4):261-4. PubMed ID: 10974577
    [Abstract] [Full Text] [Related]

  • 17. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.
    Richard MP, Aguado AG, Mattina R, Marre R.
    J Antimicrob Chemother; 1998 Feb 17; 41(2):207-14. PubMed ID: 9533462
    [Abstract] [Full Text] [Related]

  • 18. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.
    Thornsberry C, Jones ME, Hickey ML, Mauriz Y, Kahn J, Sahm DF.
    J Antimicrob Chemother; 1999 Dec 17; 44(6):749-59. PubMed ID: 10590275
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance.
    Boswell FJ, Andrews JM, Jevons G, Wise R.
    J Antimicrob Chemother; 2002 Oct 17; 50(4):495-502. PubMed ID: 12356793
    [Abstract] [Full Text] [Related]

  • 20. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
    Sader HS, Gales AC, Granacher TD, Pfaller MA, Jones RN, SENTRY Study Group (Latin America).
    Braz J Infect Dis; 2000 Oct 17; 4(5):245-54. PubMed ID: 11063556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.